Mydecine Innovations Group Adds Former Pfizer, Novartis, Yale Drug Discovery Expert to Scientific Advisory Board
VANCOUVER, British Columbia, June 30, 2020 /CNW/ -- Mydecine Innovations Group Inc. (CSE: MYCO) (OTC: MYCOF) (FSE:0NF) ("Mydecine" or the "Company"), is pleased to announce that it has added world renowned drug discovery expert Dr. Denton Hoyer to its Scientific Advisory Board.
Dr. Hoyer has been involved in drug discovery at leading pharmaceutical companies and research institutions for the last 30 years. He holds numerous patents and has been published extensively in the field of medicinal chemistry and drug research. Dr. Hoyer has unparalleled expertise in computational chemistry enabled probe molecule design, drug design and optimization, synthetic planning and execution, evaluation of chemical novelty and intellectual property assessment and strategies.
As part of his role with the company, Dr. Hoyer will directly work with Mydecine CSO Rob Roscow in developing research strategies, computational assessment of drug properties, formulation and pharmacokinetic studies as well as synthetic chemistry of drug substances.
"Dr. Hoyer's decades of experience in drug discovery, genetics, pharmacology and intellectual property are going to be instrumental to our long term success," expressed Rob Roscow.
Most recently, Dr. Hoyer served as the Director of Chemistry for the Yale Center for Molecular Discovery, where he led a team of scientists collaborating with Yale investigators to translate academic research into novel therapies for diseases across multiple therapeutic areas.
During his time at Pfizer, Dr. Hoyer held a joint appointment to both medicinal and computational groups developing a unique perspective and approach to lead finding and optimization. His deep knowledge of ADME and in-silico filtering provided Pfizer with novel properties screens and improved the quality of their screening collections. While at Novartis, Dr. Hoyer worked on compounding physical properties and ADME and created a novel approach to solubility determinations, later dubbed "kinetic" solubility.
Dr. Hoyer TSX obtained his Ph.D. with A. I. Meyers at Colorado State University developing new synthetic methodology followed by post-doctoral studies in Chemical Biology with Peter G. Schultz at the University of California, Berkeley.
"Dr. Hoyer will provide Mydecine strategic support with the entire process of drug discovery from target conception, through drug design and selection of clinical candidates. He will be instrumental to our R&D efforts at our Innovation center in Denver as well as the University of Alberta," added Mydecine CEO Josh Bartch.
About Mydecine Innovations Group Inc.
Mydecine Innovations Group is a life sciences company dedicated to the development and commercialization of adaptive pathway medicines, natural health products and digital health solutions. Mydecine's experienced cross functional teams have the capabilities to oversee all areas of drug development including synthesis, drug delivery system development, clinical trial execution, through to product commercialization and marketing. By leveraging strategic partnerships with scientific, medical, military, and clinical organizations Mydecine is at the forefront of the efficient development of psychedelic derived medicines and therapeutic solutions. Our trailblazing portfolio of companies is focused on providing innovative and effective treatment options that can help millions of people live healthier lives.
For further information about Mydecine Innovations Group Inc., please consult the Company's profile on SEDAR at www.sedar.com or visit the Company's website at http://mydecine.com/. For further information about We Are Kured, please visit their website at www.wearekured.com.
The Canadian Securities Exchange has neither approved nor disapproved the contents of this news release and accepts no responsibility for the adequacy or accuracy hereof.
This news release contains forward-looking statements, which relate to future events or future performance and reflect management's current expectations and assumptions. Such forward-looking statements reflect management's current beliefs and are based on assumptions made by and information currently available to the Company. Readers are cautioned that these forward looking statements are neither promises nor guarantees, and are subject to risks and uncertainties that may cause future results to differ materially from those expected including, but not limited to completion of planned improvements at both the Canadian and US sites on schedule and on budget, the availability of financing needed to complete the Company's planned improvements on commercially reasonable terms, planned occupancy by the tenant-growers, commencement of operations, differences in yield on expected harvests, delays in obtaining statutory approval for marijuana production plans, issues that may arise throughout the grow period, outdoor crops affected by weather, the ability to mitigate the risk of loss through appropriate insurance policies, and the risks presented by federal statutes that may contradict local and state legislation respecting legalized marijuana. These forward-looking statements are made as of the date hereof and the Company does not assume any obligation to update or revise them to reflect new events or circumstances save as required under applicable securities legislation. This news release does not constitute an offer to sell securities and the Company is not soliciting an offer to buy securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such jurisdiction.
This news release does not constitute an offer of securities for sale in the United States. These securities have not and will not be registered under United States Securities Act of 1933, as amended, or any state securities laws and may not be offered or sold in the United States or to a U.S. Person unless so registered, or an exemption from registration is relied upon.
On Behalf of the Board of Directors
For Further Information Contact
Chief Executive Officer
SOURCE Mydecine Innovations Group Inc.
Released June 30, 2020